Loading provider…
Loading provider…
Neurology Physician in Nashville, TN
NPI: 1164435004Primary Practice Location
VANDERBILT UNIVERSITY MEDICAL CENTER
2200 Childrens Way, Nashville, TN
Primary Employer
Vanderbilt Medical Group
vanderbilthealth.com
HQ Phone
Get MD Ryan's Phone NumberMobile
Get MD Ryan's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardIL State Medical License
TN State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 148 | 204 |
| 2 | 99215Established patient office or other outpatient, visit typically 40 minutes | 40 | 68 |
| 3 | 99205New patient office or other outpatient visit, typically 60 minutes | 23 | 23 |
| 4 | 99213Established patient office or other outpatient visit, typically 15 minutes | 13 | 15 |
Blood pressure fluctuations in posterior reversible encephalopathy syndrome.
Authors: Rabinstein, Alejandro A, Mandrekar, Jay, Merrell, Ryan, Kozak, Osman S, Durosaro, Olayemi, Fugate, Jennifer E
Journal: J Stroke Cerebrovasc Dis
Publication Date: 2011-05-04
Authors: Daniel Lachance, Francis Ali-Osman, Elizabeth Claus, Rose Lai
Journal: Cancer Epidemiol Biomarkers Prev
Authors: Priya Kumthekar, Rimas Lukas, Bakhtiar Yamini, Karan Dixit, Steven Chmura, Roger Stupp
Journal: Neurooncol Adv
Publication Date: 2024-02-01
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: DRUG: Temozolomide, OTHER: Laboratory Biomarker Analysis, OTHER: Quality-of-Life Assessment, DRUG: Veliparib, OTHER: Placebo Administration
Lead Sponsor: Precision Life Sciences Group
Collaborators: Medelis Inc.
Intervention / Treatment: BIOLOGICAL: Placebo, BIOLOGICAL: ICT-107
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: PROCEDURE: Magnetic Resonance Imaging, BIOLOGICAL: Nivolumab, BIOLOGICAL: Ipilimumab